CSPC Innovation Pharmaceutical (300765) Q2 2024 earnings summary

Executive summary

• Revenue for H1 2024 was ¥971.86 million, down 27.71% year-over-year, mainly due to lower caffeine prices.

• Net profit attributable to shareholders was ¥137.03 million, a 48.27% decrease year-over-year.

• Gross margin was 44.08%, down 3.63 percentage points from the prior year.

• The company completed the acquisition of a 51% stake in Jushi Biotech, expanding into innovative biologics.

• No interim dividend, bonus shares, or capital reserve transfer was planned for the period.

Financial highlights

• Operating income fell to ¥971.86 million from ¥1,344.31 million year-over-year.

• Net profit attributable to shareholders dropped to ¥137.03 million from ¥264.90 million year-over-year.

• Basic and diluted EPS were both ¥0.10, down 47.37% year-over-year.

• Net cash flow from operating activities was -¥941.44 million, compared to ¥530.10 million in the prior year, mainly due to R&D payments for Jushi Biotech.

• Total assets at period-end were ¥5.89 billion, down 21.23% from year-end 2023.

Outlook and guidance

• The company aims to strengthen its position in functional ingredients and health foods, while accelerating R&D and commercialization in biologics.

• Plans to optimize product structure, expand overseas markets, and enhance innovation in biologics.

• Will continue to invest in R&D and pursue internationalization of innovative products.